Streptococcus Pneumoniae Infection

Infectious Diseases
2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 2 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

FP
Fosun PharmaAustralia - Sydney
1 program
1
13-valent pneumococcal conjugate vaccinePhase 3Vaccine1 trial
Active Trials
NCT05759520Active Not Recruiting1,800Est. Jun 2025
M&
Merck & Co.RAHWAY, NJ
2 programs
1
Prevnar 13®Phase 1/21 trial
Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial VirusN/A1 trial
Active Trials
NCT05017519Not Yet Recruiting240Est. Jul 2026
NCT02037984Completed341Est. Jul 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Fosun Pharma13-valent pneumococcal conjugate vaccine
Merck & Co.Prevnar 13®
Merck & Co.Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial Virus

Clinical Trials (3)

Total enrollment: 2,381 patients across 3 trials

NCT05759520Fosun Pharma13-valent pneumococcal conjugate vaccine

Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants

Start: Nov 2022Est. completion: Jun 20251,800 patients
Phase 3Active Not Recruiting

Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)

Start: Jan 2014Est. completion: Jul 2016341 patients
Phase 1/2Completed
NCT05017519Merck & Co.Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial Virus

Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial Virus

Start: Oct 2021Est. completion: Jul 2026240 patients
N/ANot Yet Recruiting

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space